Articles tagged "Post-transplant malignancy"

2016 American Transplant Congress
Outcomes of Solid Organ Transplant Recipients with Pre-Existing Malignancies.
S. Acuna,^1,2,3 R. Sutradhar,^1,2 J. Kim,^1,2,4 N. Baxter.^1,2,3
¹Institute of Health Policy, Management and Education, University of Toronto, Toronto, ON, Canada; ²Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; ³Department of Surgery, St. Michael's Hospital, Toronto, ON, Canada; ⁴Department of Medicine, University Health Network, Toronto, ON, Canada.
Background: Pre-transplant malignancy (PTM) is considered a relative contraindication for transplantation due to the heightened risk of cancer recurrence associated with immunosuppression. However, little has…
2016 American Transplant Congress
Calcineurin Inhibitors Promote Metastasis in Post-Transplant Colorectal Cancer Through Cancer Related- Exosomes Released from Cancer Cells in TGF Beta Independent Epitheilal to Mesenquimal Transition.
V. Tubita,¹ J. Segui-Barber,⁴ M.-J. Ramírez-Bajo,¹ D. Moya-Rull,¹ P. Piselli,³ D. Verdirosi,³ F. Oppenheimer,^1,2,5 D. Serraino,⁶ H. Del Portillo,^4,7 F. Diekmann,^1,2,5 J. Campistol,^1,2,5 I. Revuelta.^1,2,5
¹Experimental Laboratory of Nephrology and Kidney Transplant, IDIBAPS, Barcelona, Spain; ²Department of Nephrology and Kidney Transplant, Hospital Clínic, Barcelona, Spain; ³Dipartamento di Epidemiologia e Ricerca Pre-Clinica, INMI “L. Spallanzani” IRCCC, Rome, Italy; ⁴ISGlobal, CRESIB, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; ⁵National Network for Kidney Research (REDinREN), Carlos III Royal Institute, Ministry of Health, Madrid, Spain; ⁶IRCCS Centro di Riferimento Oncologico, Aviano, Italy; ⁷Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
Introduction: Cancer is one of the major causes of death in kidney transplantation. Despite more mortality in colon cancer (CRC), similar incidence than general population…
2016 American Transplant Congress
Long Term Outcome of Kidney Transplant Recipients Treated with Everolimus: Final 5-Years Results from the Certic Observational Study.
L. Furian,¹ L. Di Maria,² G. Cappelli,³ M. Carmellini,⁴ G. Spagnoletti,⁵ G. Piredda,⁶ P. Todeschini,⁷ S. Chiaramonte,⁸ G. Tisone.⁹
¹AOU di Padova, Padova, Italy; ²AOU Careggi, Firenze, Italy; ³AOUP di Modena, Modena, Italy; ⁴AOU Senese, Siena, Italy; ⁵PU A.Gemelli, Roma, Italy; ⁶AO G.Brotzu, Cagliari, Italy; ⁷AOP S.Orsola-Malpighi, Bologna, Italy; ⁸PO S.Bortolo, Vicenza, Italy; ⁹Fondazione PU Tor Vergata, Roma, Italy.
Everolimus is associated with long-term benefits, such as preserving renal function and reducing the incidence of infections, malignancies and major cardiovascular events (MACE). The Certic…
2015 American Transplant Congress
Detecting Bowel Cancer in Pre-Dialysis, Dialysis Patients and Kidney Transplant Recipients – The DETECT Study
G. Wong, J. Chapman, J. Craig.
University of Sydney, Sydney, NSW, Australia.
Background: Colorectal cancer (CRC) is the third most common solid organ cancer in people living with kidney disease, and has a very poor prognosis, with…
2015 American Transplant Congress
Deficiency of Naturally Occurring Anti-Angiogenic Antibodies Associate With the Development of Metastatic Cancer Post Renal Transplantation and Patient Death
R. Carroll,¹ A. Phillippe,² R. Catar,² H. Heidecke,² D. Dragun.²
¹Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, SA, Australia; ²Centre for Cardiovascular Research, Charite Hospital, Berlin, Germany.
We assessed the presence of naturally occurring blocking antibodies to mediators of vascularisation and metastasis in Kidney Transplant Recipients (KTR) with metastatic cancer (n=11), non…
2015 American Transplant Congress
Elevated Cancer Risk Among US Pediatric Solid Organ Transplant Recipients
E. Yanik,¹ J. Smith,² M. Shiels,¹ C. Clarke,³ C. Lynch,⁴ A. Kahn,⁵ L. Koch,⁶ K. Pawlish,⁷ E. Engels.¹
¹Natl. Cancer Inst., Bethesda, MD; ²Seattle Children's Hosp., Seattle, WA; ³Cancer Prev. Inst. of CA, Fremont, CA; ⁴U. of Iowa, Iowa City, IA; ⁵NY St. Cancer Reg., Albany, NY; ⁶IL St. Cancer Reg., Springfield, IL; ⁷NJ St. Cancer Reg., Trenton, NJ.
Among pediatric transplant recipients, the effects of transplantation and immunosuppression on cancer risk may be unique from those observed in the adult transplant population. No…
2015 American Transplant Congress
Pre-Transplant Desensitization Protocol and Cancer Risk in Kidney Transplantation
I. Revuelta,^1,2,3 R. Ferreira,¹ C. Canha,¹ P. Piselli,⁴ D. Verdirosi,⁴ V. Tubita,² E. De Sousa,¹ F. Diekmann,^1,2,3 M. Lozano,^2,5 J. Cid,⁵ E. Palou,⁶ J. Martorell,⁶ A. Alcaraz,⁷ D. Serraino,⁸ F. Oppenheimer,^1,2,3 J. Campistol.^1,2,3
¹Renal Transplant Unit, Department of Nephrology and Kidney Transplant, Hospital Clinic, Barcelona, Spain; ²IDIBAPS, Barcelona, Spain; ³REDinREN. Carlos III Royal Institute. Ministry of Health, Madrid, Spain; ⁴Dipartamento di Epidemiologia e Ricerca Pre-Clinica, INMI “L. Spallanzani” IRCCC, Rome, Italy; ⁵Hemotherapy and Hemostasis, Hospital Clinic, Barcelona, Spain; ⁶Department of Immunology, Hospital Clinic, Barcelona, Spain; ⁷Department of Urology, Hospital Clinic, Barcelona, Spain; ⁸IRCCS Centro di Riferimento Oncologico, Aviano, Italy.
Introduction: Desensitization (DS) in kidney transplant is a current therapy for all cause of incompatible living donor kidney transplants (LDKT). The impact in cancer risk…
2015 American Transplant Congress
The Onset of Post-Transplant Malignancies Is Related to a Change in Gene Expression Profiles in Peripheral Blood Mononuclear Cells
G. Stallone,¹ R. Federica,¹ P. Pontrelli,² M. Accetturo,² A. Oranger,² M. Gigante,² G. Castellano,² A. Schena,² M. Fiorentino,² B. Infante,¹ L. Gesualdo,² G. Grandaliano.¹
¹Dept.of Surgical and Medical Sciences, Nephrology Unit, University of Foggia, Foggia, Italy; ²Dept. of Emergency and Organ Transplantation, Nephrology Unit, University of Bari, Bari, Italy.
Malignancies are the third leading cause of death in renal transplant recipients and their incidence is increasing. Although the role of the immune system in…
2015 American Transplant Congress
24 Month Post Transplantation Follow Up of the Certitem Trial
E. Rondeau,¹ E. Cassuto,² V. Vuiblet,³ C. Legendre,⁴ P. Merville,⁵ Y. Le Meur,⁶ B. Moulin,⁷ P. Westeel,⁸ B. Hurault De Ligny,⁹ A. Lécuyer,¹⁰ M. Tindel,¹¹ N. Kamar.¹²
¹Hôpital Tenon, Paris, France; ²Hôpital Pasteur, Nice, France; ³Hôpital Maison Blanche, Reims, France; ⁴Hôpital Necker, Paris, France; ⁵Hôpital Pellegrin, Bordeaux, France; ⁶Hôpital La Cavale Blanche, Brest, France; ⁷Nouvel Hôpital Civil, Strasbourg, France; ⁸Hôpital Sud, Amiens, France; ⁹CHU, Caen, France; ¹⁰Novartis Pharma S.A.S, Rueil-Malmaison, France; ¹¹Keyrus Biopharma, Levallois-Perret, France; ¹²Hôpital Rangueil, Toulouse, France.
Background: CERTITEM has evaluated the effect of everolimus/calcineurin inhibitors free (CNI free) on fibrosis progression and results have been reported at 12 months (M12). Data…
2015 American Transplant Congress
Verification of OPTN Hepatocellular Carcinoma Recurrence Data
J. George,¹ K. Eddinger,¹ D. Goldberg,² M. Levine,³ P. Abt.³
¹Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA; ²Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA; ³Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA.
PURPOSE: OPTN data on HCC recurrence is increasingly utilized for a variety of studies; however, the accuracy of this data has not been examined. We…